{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:53:30Z","timestamp":1793224410130,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101034290"],"award-info":[{"award-number":["101034290"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ymthe.2025.12.005","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:21:12Z","timestamp":1765297272000},"page":"1399-1420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bispecific BAFF-R\/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma"],"prefix":"10.1016","volume":"34","author":[{"given":"Agnese","family":"Fiori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Erdlei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyan","family":"Jayarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gr\u00fcnschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Ortiz-Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe-Jens","family":"Te\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soungchul","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigen","family":"Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Valamehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta E.","family":"H\u00f6pken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-1950","authenticated-orcid":false,"given":"Armin","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.12.005_bib1","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2025.12.005_bib2","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3324\/haematol.2020.266858","article-title":"Novel immunotherapies in multiple myeloma - chances and challenges","volume":"106","author":"Rasche","year":"2021","journal-title":"haematol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.12.005_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.12.005_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Via","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib10","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma","volume":"1","author":"Fernandez de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.12.005_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.12.005_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.12.005_bib17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL System in Cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.12.005_bib18","doi-asserted-by":"crossref","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","article-title":"Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Camviel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.12.005_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","article-title":"A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers","volume":"13","author":"Wong","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib21","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.12.005_bib22","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib23","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1084\/jem.20100857","article-title":"A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling","volume":"207","author":"Hildebrand","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib24","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.12.005_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","article-title":"Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing","volume":"27","author":"Cohen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib27","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102913","article-title":"CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival","volume":"11","author":"Gross Even-Zohar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib31","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/blood-2005-11-4334","article-title":"Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival","volume":"107","author":"Starlets","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib32","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","article-title":"Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma","volume":"83","author":"Yao","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib33","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s41419-018-1109-5","article-title":"CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1alpha","volume":"9","author":"Lu","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2025.12.005_bib35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","article-title":"Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.12.005_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","article-title":"Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation","volume":"102","author":"Tarte","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1541-7786.MCR-21-0828","article-title":"Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma","volume":"20","author":"Cottini","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2025.12.005_bib39","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54543-0","article-title":"Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy","volume":"15","author":"Lutz","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib43","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib44","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00109-024-02470-4","article-title":"Structure-based humanization of a therapeutic antibody for multiple myeloma","volume":"102","author":"Marino","year":"2024","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib45","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1182\/bloodadvances.2024013195","article-title":"Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies","volume":"8","author":"Dong","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.12.005_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","article-title":"Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions","volume":"30","author":"Lam","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.12.005_bib47","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/2326-6066.CIR-24-1347","article-title":"CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target","volume":"13","author":"Shukla","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib49","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.12.005_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383136","article-title":"CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma","volume":"15","author":"Moles","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.20071088","article-title":"Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation","volume":"205","author":"Meyer-Bahlburg","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","article-title":"Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease","volume":"244","author":"Rickert","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2025.12.005_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ceb.2017.10.002","article-title":"Signalling for B cell survival","volume":"51","author":"Schweighoffer","year":"2018","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ymthe.2025.12.005_bib58","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.12.005_bib60","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","article-title":"Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies","volume":"14","author":"Ruella","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ymthe.2025.12.005_bib62","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.clml.2016.02.025","article-title":"Clonal Evolution in Multiple Myeloma","volume":"16","author":"Fakhri","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ymthe.2025.12.005_bib63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib65","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","article-title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function","volume":"7","author":"Leung","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.12.005_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.12.005_bib67","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.12.005_bib68","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.138826","article-title":"The myeloma stem cell concept, revisited: from phenomenology to operational terms","volume":"101","author":"Johnsen","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.12.005_bib69","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.12.005_bib70","doi-asserted-by":"crossref","first-page":"W207","DOI":"10.1093\/nar\/gkad347","article-title":"g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)","volume":"51","author":"Kolberg","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.12.005_bib71","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.12.005_bib72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12859-021-04054-2","article-title":"CytoTree: an R\/Bioconductor package for analysis and visualization of flow and mass cytometry data","volume":"22","author":"Dai","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ymthe.2025.12.005_bib73","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.ymthe.2022.07.009","article-title":"EBAG9 silencing exerts an immune checkpoint function without aggravating adverse effects","volume":"30","author":"Wirges","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625010287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:36:27Z","timestamp":1776371787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625010287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1525001625010287"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific BAFF-R\/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}